AMRN vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMRN's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining revenue, and negative earnings trends. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given the company's negative ROE, ROA, and persistent losses despite a strong gross margin. While the company exhibits a low debt-to-equity ratio and high liquidity, these strengths are overshadowed by a 21% YoY revenue decline and a 94.7% Q/Q EPS drop. Analysts have issued a 'underperform' rating with a target price below current levels, reflecting skepticism about near-term sustainability. The stock's recent 87% 1-year gain is likely driven by speculative momentum rather than fundamentals.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AMRN vs LLY: Head-to-Head Comparison
This page compares Amarin Corporation plc (AMRN) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.